bioRxivPathologyPreprint
Myeloperoxidase promotes fibrosis by inhibiting cathepsin K to bias the lung toward ECM accumulation
Patrick A. LinkiD, Jack H. WellmerlingiD, Jeffrey A. Meridew, Hyogo Naoi, Y. S. PrakashiD, Mauricio M. RojasiD, Eva M. CarmonaiD, Daniel J. TschumperliniD
Abstract
Pulmonary fibrosis (PF) involves excessive collagen accumulation, yet mechanisms shifting the balance of synthesis and degradation toward net deposition remain unclear. Myeloperoxidase (MPO) inversely correlates with survival in PF. Using the bleomycin model, we found MPO knockout (MPOko) mice were protected from fibrosis, and pharmacological MPO inhibition after peak inflammation (day 7) recapitulated this protection. MPO persisted in lung tissue 21 days post-injury despite neutrophil efflux, linking acute inflammation to sustained remodeling. Mechanistically, we identified that MPO inhibits Cathepsin K (CatK), a potent collagenolytic enzyme involved in fibrosis resolution. Notably, CatK gene expression (CTSK) is elevated in PF, suggesting post-translational inhibition of CatK. MPOko and inhibitor-treated mice exhibited elevated CatK activity after bleomycin; exogenous addition of pathophysiologic concentrations of MPO reduced CatK activity in mouse precision-cut lung slices and human fibroblasts. Biochemically, MPO reduced CatK activity to 33% of control. In two distinct cohorts of PF patients, we observed significantly increased MPO protein levels in platelet poor plasma and in lung tissue. In PF patients, 62% had MPO levels in platelet poor plasma exceeding healthy controls, while lung tissue from other PF patients showed significantly elevated MPO staining. Plasma levels were inversely correlated with decreased survival, FVC, and DLCO. These findings establish MPO as a post-translational inhibitor of CatK-mediated collagenolysis, revealing a mechanism linking acute inflammation to sustained fibrosis and suggest a patient subpopulation that may benefit from MPO-targeted therapy. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=54 SRC="FIGDIR/small/713467v1_ufig1.gif" ALT="Figure 1"> View larger version (17K): org.highwire.dtl.DTLVardef@90789forg.highwire.dtl.DTLVardef@df248dorg.highwire.dtl.DTLVardef@1d8dfe6org.highwire.dtl.DTLVardef@1538145_HPS_FORMAT_FIGEXP M_FIG C_FIG Myeloperoxidase persists in lung tissue after injury and inhibits cathepsin K activity, impairing collagen degradation and promoting extracellular matrix accumulation during pulmonary fibrosis.
- organism: mouse
- organism: human
- assay: proteomics
- research focus: differential expression
- research focus: cell-cell communication
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mechanosignaling Promotes Macrophage Apoptosis Resistance in Pulmonary Fibrosis via Metabolic Reprogramming
Chao He, Cristian Coarfa, … Iván O. Rosas·bioRxiv·Sep 28, 2026
- Immunomodulatory nanoparticles elicit antifibrotic monocyte activation to resolve murine pulmonary fibrosis
Hannah Viola, Hannah M. Carter, … Lonnie Shea·bioRxiv·Dec 24, 2025
- Legumain (asparaginyl endopeptidase) modulates extracellular matrix dynamics in pulmonary fibrosis
Baptiste Rigoux, Alexis David, … Ahlame Saidi·bioRxiv·Jul 21, 2026
- Macropinocytosis inhibition attenuates pro-fibrotic responses in lung fibroblasts and pulmonary fibrosis
Iván O. Rosas, Aaron K McDowell-Sanchez, … Konstantin Tsoyi·bioRxiv·Jul 9, 2025
- Modeling Mechanical Activation of Macrophages During Pulmonary Fibrogenesis for Targeted Anti-Fibrosis Therapy
- Pharmacological Inhibition of Epac1 Protects against Pulmonary Fibrosis by Blocking FoxO3a Neddylation
Katherine Jankowski, Sarah-Eve S Lemay, … Lahouaria Hadri·European Respiratory JournalPeer-reviewed·Jul 10, 2025